ASXL1 and myeloproliferative neoplasm: As expected, the three common variants in the ML cohort were TET2 (71.1%), GATA2 (38.7%), and ASXL1 (28.9%); in MDS, TET2 (66.4%), GATA2 (41.2%), and ASXL1 (33.6%); and in MPN and MPN/MDS, ASXL1 (83.3%), TET2 (75%), NRAS (33.3%), and SH2B3 (33.3%).